Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib-Reference-Cited by-同舟云学术

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Published:2024-02 Issue:2 Volume:14 Page:517-532
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Xiang Shuang,Lu Xiaoyun^ORCID

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference125 articles.

1. Neurotrophins: roles in neuronal development and function;Huang;Annu Rev Neurosci,2001

2. Trk receptor tyrosine kinases: a bridge between cancer and neural development;Nakagawara;Cancer Lett,2001

3. Autophosphorylation of activation loop tyrosines regulates signaling by the TRK nerve growth factor receptor;Cunningham;J Biol Chem,1997

4. A function-structure model for NGF-activated TRK;Cunningham;Embo J,1998

5. TRKing down an old oncogene in a new era of targeted therapy;Vaishnavi;Cancer Discov,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

2. Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights;Molecules;2024-07-29

3. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors;Acta Neuropathologica Communications;2024-07-16

4. Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC;Frontiers in Surgery;2024-06-14

5. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives;International Journal of Molecular Sciences;2024-05-17